Implantable vagal stimulator led to benefit in TNF-inadequate responder RA in this sham-controlled double-blind RCT (RESET-RA study) - 82% off b/tsDMARDs at 12mo - also with benefit to control group after crossover at 3mo to an active device #ACR25 1675 @RheumNow https://t.co/yYwWCKm6HF